CD274 and hepatocellular carcinoma: Recently, combined immunotherapy with phase III IMbrave150 and the PD-L1 inhibitor atezolizumab plus anti-angiogenesis bevacizumab showed more convincing effects than monotherapy in advanced HCC patients (37,38).